Top-Rated StocksTop-RatedNASDAQ:CNTA Centessa Pharmaceuticals (CNTA) Stock Price, News & Analysis $12.92 -0.04 (-0.27%) As of 02:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Centessa Pharmaceuticals Stock (NASDAQ:CNTA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CNTA alerts:Sign Up Key Stats Today's Range$12.87▼$13.3350-Day Range$10.71▼$16.6352-Week Range$7.75▼$19.09Volume331,783 shsAverage Volume652,627 shsMarket Capitalization$1.73 billionP/E RatioN/ADividend YieldN/APrice Target$27.89Consensus RatingBuy Company OverviewCentessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.Read More… Centessa Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreCNTA MarketRank™: Centessa Pharmaceuticals scored higher than 69% of companies evaluated by MarketBeat, and ranked 317th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingCentessa Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCentessa Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Centessa Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Centessa Pharmaceuticals are expected to grow in the coming year, from ($1.60) to ($1.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Centessa Pharmaceuticals is -8.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Centessa Pharmaceuticals is -8.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCentessa Pharmaceuticals has a P/B Ratio of 5.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Centessa Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.51% of the float of Centessa Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCentessa Pharmaceuticals has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Centessa Pharmaceuticals has recently increased by 3.56%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCentessa Pharmaceuticals does not currently pay a dividend.Dividend GrowthCentessa Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.51% of the float of Centessa Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCentessa Pharmaceuticals has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Centessa Pharmaceuticals has recently increased by 3.56%, indicating that investor sentiment is decreasing. News and Social Media3.3 / 5News Sentiment0.96 News SentimentCentessa Pharmaceuticals has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Centessa Pharmaceuticals this week, compared to 5 articles on an average week.Search Interest2 people have searched for CNTA on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Centessa Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Centessa Pharmaceuticals insiders have bought 129.94% more of their company's stock than they have sold. Specifically, they have bought $5,866,687.00 in company stock and sold $2,551,442.00 in company stock.Percentage Held by InsidersOnly 7.09% of the stock of Centessa Pharmaceuticals is held by insiders.Percentage Held by Institutions82.01% of the stock of Centessa Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Centessa Pharmaceuticals' insider trading history. Receive CNTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Centessa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CNTA Stock News HeadlinesGregory M. Weinhoff Sells 10,000 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) StockMay 28 at 5:07 AM | insidertrades.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Director Buys $550,053.36 in StockMay 20, 2025 | insidertrades.comThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?May 29, 2025 | Timothy Sykes (Ad)Centessa Pharmaceuticals plc (NASDAQ:CNTA) General Counsel Iqbal J. Hussain Sells 2,080 SharesApril 30, 2025 | insidertrades.comNeedham & Company LLC Begins Coverage on Centessa Pharmaceuticals (NASDAQ:CNTA)May 29 at 2:01 AM | americanbankingnews.comCentessa Pharmaceuticals (NASDAQ:CNTA) Upgraded at Wall Street ZenMay 25, 2025 | americanbankingnews.comCentessa Pharmaceuticals (NASDAQ:CNTA) Shares Gap Up After Insider Buying ActivityMay 22, 2025 | americanbankingnews.comArjun Goyal Buys 417,646 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) StockMay 21, 2025 | americanbankingnews.comSee More Headlines CNTA Stock Analysis - Frequently Asked Questions How have CNTA shares performed this year? Centessa Pharmaceuticals' stock was trading at $16.75 at the beginning of the year. Since then, CNTA stock has decreased by 22.9% and is now trading at $12.9150. View the best growth stocks for 2025 here. How were Centessa Pharmaceuticals' earnings last quarter? Centessa Pharmaceuticals plc (NASDAQ:CNTA) announced its quarterly earnings results on Monday, May, 12th. The company reported ($0.20) earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.15. When did Centessa Pharmaceuticals IPO? Centessa Pharmaceuticals (CNTA) raised $285 million in an initial public offering on Friday, May 28th 2021. The company issued 15,000,000 shares at $18.00-$20.00 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Jefferies and Evercore ISI were co-managers. Who are Centessa Pharmaceuticals' major shareholders? Centessa Pharmaceuticals' top institutional shareholders include Adage Capital Partners GP L.L.C. (5.21%), Price T Rowe Associates Inc. MD (4.01%), First Light Asset Management LLC (3.65%) and Siren L.L.C. (2.22%). Insiders that own company stock include Antoine Yver, Arjun Goyal, David M Chao, Saurabh Saha, Thomas Templeman, Gregory M Weinhoff, Tia L Bush, Iqbal J Hussain, Harris Rotman and Karen M Anderson. View institutional ownership trends. How do I buy shares of Centessa Pharmaceuticals? Shares of CNTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Centessa Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Centessa Pharmaceuticals investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), TotalEnergies (TTE), The RMR Group (RMR) and Southern First Bancshares (SFST). Company Calendar Last Earnings5/12/2025Today5/29/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CNTA CIK1847903 Webwww.centessa.com Phone44-73-9178-9784FaxN/AEmployees200Year FoundedN/APrice Target and Rating Average Stock Price Target$27.89 High Stock Price Target$38.00 Low Stock Price Target$6.00 Potential Upside/Downside+115.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($1.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$151.09 million Net MarginsN/A Pretax Margin-2,310.33% Return on Equity-52.13% Return on Assets-38.01% Debt Debt-to-Equity Ratio0.15 Current Ratio21.52 Quick Ratio21.52 Sales & Book Value Annual Sales$15 million Price / Sales115.03 Cash FlowN/A Price / Cash FlowN/A Book Value$2.42 per share Price / Book5.34Miscellaneous Outstanding Shares133,598,000Free Float116,564,000Market Cap$1.73 billion OptionableOptionable Beta1.53 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:CNTA) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Centessa Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Centessa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.